Evidence map›Paper›PMID 19185844›Full record

ArticleCancer cell2009

gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis.

Julia Bollrath, Toby J Phesse, Vivian A von Burstin, Tracy Putoczki, Moritz Bennecke, Trudie Bateman, Tim Nebelsiek, Therese Lundgren-May, Ozge Canli, Sarah Schwitalla and 6 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Cancer cell, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 512 papers.

0numbers the graph read from it
0cells of the map it votes in
512citing papers in PubMed
33.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

512 citing papers in PubMed, 932 citations in OpenAlex.

  1. Review
  2. Article
  3. Pathophysiology of colitis-associated colorectal cancer.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Cellular signaling meets bacterial infection: the integrative role of STAT3.Frontiers in cellular and infection microbiology · 2026
    Review
  13. Review
  14. Article
  15. Lipid nanomedicine simultaneously inhibits BRD4/PI3K and MDM2/XIAP signaling pathways for effective treatment of Medulloblastoma.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  16. STAT3 Inhibition to Treat Ulcerative Colitis-Associated Colorectal Cancer.International journal of molecular sciences · 2025
    Article
  17. IL-6 Inhibits Invasion in a Murine Model of Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2025
    Article
  18. Constructing a chemokine-based model and identifyingTranslational cancer research · 2025
    Article
  19. Review
  20. NF-κB in inflammation and cancer.Cellular & molecular immunology · 2025
    Review

452 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Julia Bollrath2nd Department of Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Toby J Phesse
Vivian A von Burstin
Tracy Putoczki
Moritz Bennecke
Trudie Bateman
Tim Nebelsiek
Therese Lundgren-May
Ozge Canli
Sarah Schwitalla
Vance Matthews
Roland M Schmid
Thomas Kirchner
Melek C Arkan
Matthias Ernst
Florian R Greten
TUM Klinikum · DEThe Royal Melbourne Hospital · AULudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although gastrointestinal cancers are frequently associated with chronic inflammation, the underlying molecular links have not been comprehensively deciphered. Using loss- and gain-of-function mice in a colitis-associated cancer model, we establish here a link comprising the gp130/Stat3 transcription factor signaling axis. Mutagen-induced tumor growth and multiplicity are reduced following intestinal epithelial cell (IEC)-specific Stat3 ablation, while its hyperactivation promotes tumor incidence and growth. Conversely, IEC-specific Stat3 deficiency enhances susceptibility to chemically induced epithelial damage and subsequent mucosal inflammation, while excessive Stat3 activation confers resistance to colitis. Stat3 has the capacity to mediate IL-6- and IL-11-dependent IEC survival and to promote proliferation through G1 and G2/M cell-cycle progression as the common tumor cell-autonomous mechanism that bridges chronic inflammation to tumor promotion.

Indexed as

ColitisNeoplasmsAnimalsApoptosisCell CycleCell Cycle ProteinsCell ProliferationCell SurvivalCytokine Receptor gp130EnterocytesHumansInflammationInterleukin-11Interleukin-6Intestinal MucosaMiceCell Cycle ProteinsCytokine Receptor gp130Interleukin-11Interleukin-6STAT3 Transcription Factor

Identifiers

PMID19185844
OpenAlexW2105269215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.